enVVeno Medical Corp expected to post a loss of 40 cents a share - Earnings Preview
Brief: enVVeno Medical Says Co On Track To File Application Seeking VenoValve US FDA Approval In Q4 2024
enVVeno Medical Corp reports results for the quarter ended in December - Earnings Summary
enVVeno Medical Corp expected to post a loss of 46 cents a share - Earnings Preview
enVVeno Medical Corp expected to post a loss of 46 cents a share - Earnings Preview
enVVeno Medical Corp expected to post a loss of 46 cents a share - Earnings Preview
enVVeno Medical Corp expected to post a loss of 46 cents a share - Earnings Preview
Brief: enVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event Data
Brief: Envveno Medical Corp Files Prospectus For Resale By Selling Stockholders Of Up To 14.70 Million Shares Of Common Stock
enVVeno Medical Corp reports results for the quarter ended in September - Earnings Summary
enVVeno Medical Corp expected to post a loss of 48 cents a share - Earnings Preview
Brief: Envveno Medical Corp Files For Mixed Shelf Of Up To $75 Million – SEC Filing
Brief: Hancock Jaffe Laboratories - Entered Into At--Market Offering Agreement With Ladenburg Thalmann To Create At--Market Equity Program
Hancock Jaffe Laboratories Inc reports results for the quarter ended in June - Earnings Summary
Hancock Jaffe Labs rises as product gets FDA's breakthrough designation
Hancock Jaffe Laboratories Inc reports results for the quarter ended in March - Earnings Summary
Brief: Hancock Jaffe Laboratories Says Craig Glynn Has Accepted Position Of CFO
Brief: Hancock Jaffe Laboratories Files For Common Stock Offering Of Up To $15.0 Mln - SEC Filing
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:14 PM